USO 23245
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma
Disease Types: Cellular & Gene
Eligibility Requirements:
• Subject must have received at least 4 classes of treatment
(including an IMiD, PI, anti-CD38 mAb, and anti-BCMA therapy)
• Must have undergone at least 2 consecutive cycles of
treatment for each treatment class, unless PD was the best
response or unacceptable toxicity
• Subjects must have at least 3 prior lines of therapy
• Subjects must have documented disease progression during or
after their last regimen
• Subjects with known active or history of CNS involvement of MM
are excluded
• Subjects that received prior GPRC5D-targeted therapy or
treatment for MM without the required washout prior to
leukapheresis are excluded
Available at: